Varlitinib
Sponsors
ASLAN Pharmaceuticals
Conditions
Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Solid TumorsBiliary Tract CancerCholangiocarcinomaGastric CancerHealthy Volunteers
Phase 1
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
TerminatedNCT02992340
Start: 2016-12-13End: 2020-11-24Target: 204Updated: 2021-01-14
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
CompletedNCT03082053
Start: 2017-01-31End: 2018-06-06Updated: 2018-06-28
Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib
CompletedNCT03368846
Start: 2017-11-23End: 2017-12-14Updated: 2018-09-11
Phase 2
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
CompletedNCT02609958
Start: 2015-11-16End: 2017-10-11Updated: 2018-05-29
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
CompletedNCT03093870
Start: 2017-07-04End: 2020-04-17Updated: 2021-08-03
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
CompletedNCT03130790
Start: 2017-08-31End: 2019-02-22Updated: 2022-02-15
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
WithdrawnNCT03129074
Start: 2018-05-31End: 2020-09-30Updated: 2018-05-23
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
CompletedNCT03231176
Start: 2017-12-19End: 2020-04-13Updated: 2020-11-19